Topics

ArQule to Host Analyst Call Highlighting Clinical Progress from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies

07:00 EST 29 Nov 2018 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
ArQule, Inc. (Nasdaq: ARQL) today announced that it will host a call to discuss the updated safety, PK, biomarker and anti-tumor activity data from the company’s Phase 1 dose escalation study in patients with relapsed or refra...

Other Sources for this Article

Corporate Contact:
Marc Schegerin, M.D.
Senior Vice President
Head of Strategy, Finance and Communication
ir@arqule.com

Media Contact:
Allison Blum, Ph.D.
LifeSci Public Relations (646) 627-8383
Allison@lifescipublicrelations.com
www.ArQule.com

NEXT ARTICLE

More From BioPortfolio on "ArQule to Host Analyst Call Highlighting Clinical Progress from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies"

Quick Search

Relevant Topic

Diagnostics
A diagnostic test is any kind of medical test performed to aid in the diagnosis or detection of disease. For example: to diagnose diseases to measure the progress or recovery from disease to confirm that a person is free from disease Clin...